Trial Profile
A Randomized, Single-Center, Open-Label, Three-Period, Six-Sequence, Crossover, Comparative Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Product Formulations in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2018
Price :
$35
*
At a glance
- Drugs Vapendavir (Primary)
- Indications Rhinovirus infections
- Focus Pharmacokinetics
- Sponsors Aviragen Therapeutics
- 14 Sep 2016 Results of the bioavailability study were published in an Aviragen Therapeutics financial report.
- 13 Sep 2016 New trial record